Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Metformin may delay prostate cancer progression, randomized trial suggests

Key clinical point: Adding metformin to standard care for advanced prostate cancer appeared to lengthen time to progression.

Major finding: The median time to progression to castration-resistant prostate cancer was 29 months with metformin plus standard therapy and 20 months with standard therapy alone (P = .01).

Study details: A randomized trial of 124 patients with high-risk locally advanced or metastatic hormone-sensitive prostate cancer.

Disclosures: There was no external funding for this study, and the investigators didn’t have any disclosures.


ALGhandour R et al. ESMO 2020, Abstract 617MO.